<p>安联集团在最近向证券交易委员会提交的 13F 文件中表示，在第二季度减少了对百时美施贵宝公司的持股，减幅为 5.5%。该基金在季度内出售了 5,501 股后，持有 94,623 股该生物制药公司的股票。安联集团在百时美施贵宝的持股在最近一个季度末的价值为 4,380,000 美元。</p>
<p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
<ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
<p>其他几家机构投资者最近也调整了对该股票的持股。Trifecta Capital Advisors LLC 在第二季度购买了百时美施贵宝的新头寸，价值 25,000 美元。REAP Financial Group LLC 在第二季度将其在百时美施贵宝的持股增加了 202.8%。REAP Financial Group LLC 现在拥有 639 股该生物制药公司的股票，价值 30,000 美元，此前在上个季度又收购了 428 股。Accent Capital Management LLC 在第一季度以 33,000 美元的估值购买了百时美施贵宝的新头寸。CBIZ Investment Advisory Services LLC 在第一季度将其在百时美施贵宝的持股增加了 66.0%。CBIZ Investment Advisory Services LLC 现在拥有 581 股该生物制药公司的股票，价值 35,000 美元，此前在上个季度又收购了 231 股。最后，GKV Capital Management Co. Inc.在第一季度以约 36,000 美元的估值购买了百时美施贵宝的新股份。目前 76.41% 的股票由机构投资者持有。</p>
<h2>百时美施贵宝的内部交易</h2>
<p>在其他百时美施贵宝的新闻中，执行副总裁 David V. Elkins 于 9 月 2 日星期二出售了 56,000 股公司的股票。股票以平均价格 47.33 美元出售，总价值为 2,650,480.00 美元。交易完成后，该执行副总裁直接持有 167,379 股公司股票，估值约为 7,922,048.07 美元。这代表其持股减少了 25.07%。该出售在向证券交易委员会提交的文件中披露，可以通过 SEC 网站访问。内部人士持有公司股票的 0.09%。</p>
<h2>百时美施贵宝股票下跌 0.9%</h2>
<ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
<p>周五，纽约证券交易所 BMY 的开盘价为 48.64 美元。百时美施贵宝公司的 1 年最低价为 42.52 美元，1 年最高价为 63.33 美元。该股票的市值为 990.2 亿美元，市盈率为 19.61，市盈增长比率为 2.23，贝塔系数为 0.33。公司的债务与股本比率为 2.54，流动比率为 1.21，速动比率为 1.11。该公司的 50 日移动平均线为 45.35 美元，200 日移动平均线为 46.71 美元。</p>
<p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近于 10 月 30 日星期四发布了季度财报。这家生物制药公司报告季度每股收益为 1.63 美元，超出分析师一致预期的 1.52 美元，超出幅度为 0.11 美元。百时美施贵宝的股本回报率为 80.04%，净利润率为 10.58%。该公司在本季度的收入为 122.2 亿美元，而分析师预期为 117.5 亿美元。在去年同期，该公司发布的每股收益为 1.80 美元。百时美施贵宝的季度收入较去年同期增长了 2.8%。百时美施贵宝已将其 2025 财年的指导目标设定为每股收益 6.400-6.600 美元。卖方分析师预测百时美施贵宝公司今年的每股收益将达到 6.74 美元。</p>
<h2>百时美施贵宝分红公告</h2>
<ul>
<li>百时美施贵宝的疲软指引可能创造机会</li>
</ul>
<p>该公司最近还披露了季度分红，已于 11 月 3 日星期一支付。10 月 3 日星期五的股东获得每股 0.62 美元的分红。这相当于年化分红 2.48 美元，收益率为 5.1%。该分红的除息日为 10 月 3 日星期五。百时美施贵宝的派息比率目前为 83.78%。</p>
<h2>分析师设定新目标价</h2>
<p>几家券商最近对 BMY 发表了评论。Sanford C. Bernstein 在 11 月 3 日星期一的研究报告中重申了对百时美施贵宝股票的 “市场表现” 评级。Weiss Ratings 在 10 月 14 日星期二的研究报告中重申了对百时美施贵宝股票的 “持有（c-）” 评级。摩根士丹利在 7 月 31 日星期四的研究报告中重新发布了对百时美施贵宝股票的 “持有” 评级。大和美国在 8 月 5 日星期二将百时美施贵宝的评级从 “强力买入” 下调至 “持有”。最后，大和资本市场在 8 月 5 日星期二将百时美施贵宝的评级从 “跑赢大盘” 下调至 “中性”，并设定了 42.00 美元的目标价。四位研究分析师对该股票给予了买入评级，十五位分析师对该公司给予了持有评级。根据 MarketBeat.com 的数据，百时美施贵宝的平均评级为 “持有”，平均目标价为 54.58 美元。</p>
<p><strong>阅读我们对 BMY 的最新分析</strong></p>
<h2>关于百时美施贵宝</h2>
<p>（免费报告）</p>
<p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供用于血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。公司的产品包括 Eliquis，用于降低非瓣膜性房颤患者中风/全身性栓塞的风险，以及用于治疗深静脉血栓/肺栓塞；Opdivo 用于多种抗癌适应症，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用于多发性骨髓瘤；Orencia 用于活动性类风湿关节炎和银屑病关节炎；Sprycel 用于治疗费城染色体阳性慢性髓性白血病。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过百时美施贵宝</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>尽管第三季度业绩出色，dLocal 股价仍下跌——投资者错过了什么</li>
<li>市盈率计算：如何评估股票</li>
<li>Ondas Holdings 在无人机需求激增中发出反弹信号</li>
<li>什么样的股票是好的分红股票？</li>
<li>在艾格的魔力下，迪士尼 2026 年的前景变得更加光明</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
<p>在考虑百时美施贵宝之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

百时美施贵宝

安联集团(ADR)

<p>安联集团 (ADR) 在第二季度减少了对百时美施贵宝的持股 5.5%，目前持有 94,623 股，价值 438 万美元。其他机构投资者也调整了他们的持仓。百时美施贵宝的股票开盘价为 48.64 美元，市值为 990.2 亿美元。该公司报告第三季度每股收益为 1.63 美元，超出预期，并宣布季度股息为每股 0.62 美元。分析师设定了新的价格目标，评级来自不同券商的反馈不一</p>

<p>Allianz SE lessened its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 94,623 shares of the biopharmaceutical company's stock after selling 5,501 shares during the quarter. Allianz SE's holdings in Bristol Myers Squibb were worth $4,380,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>安联集团在最近向证券交易委员会提交的 13F 文件中表示，在第二季度减少了对百时美施贵宝公司的持股，减幅为 5.5%。该基金在季度内出售了 5,501 股后，持有 94,623 股该生物制药公司的股票。安联集团在百时美施贵宝的持股在最近一个季度末的价值为 4,380,000 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
</div><p>Several other institutional investors also recently modified their holdings of the stock. Trifecta Capital Advisors LLC bought a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $25,000. REAP Financial Group LLC grew its position in Bristol Myers Squibb by 202.8% in the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 428 shares in the last quarter. Accent Capital Management LLC bought a new position in Bristol Myers Squibb in the first quarter valued at $33,000. CBIZ Investment Advisory Services LLC increased its stake in Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 231 shares during the last quarter. Finally, GKV Capital Management Co. Inc. purchased a new stake in Bristol Myers Squibb during the first quarter valued at about $36,000. 76.41% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也调整了对该股票的持股。Trifecta Capital Advisors LLC 在第二季度购买了百时美施贵宝的新头寸，价值 25,000 美元。REAP Financial Group LLC 在第二季度将其在百时美施贵宝的持股增加了 202.8%。REAP Financial Group LLC 现在拥有 639 股该生物制药公司的股票，价值 30,000 美元，此前在上个季度又收购了 428 股。Accent Capital Management LLC 在第一季度以 33,000 美元的估值购买了百时美施贵宝的新头寸。CBIZ Investment Advisory Services LLC 在第一季度将其在百时美施贵宝的持股增加了 66.0%。CBIZ Investment Advisory Services LLC 现在拥有 581 股该生物制药公司的股票，价值 35,000 美元，此前在上个季度又收购了 231 股。最后，GKV Capital Management Co. Inc.在第一季度以约 36,000 美元的估值购买了百时美施贵宝的新股份。目前 76.41% 的股票由机构投资者持有。</p>
</div><h2>Insider Transactions at Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>百时美施贵宝的内部交易</h2>
</div><p>In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Insiders own 0.09% of the company's stock.</p>
<div class="lb-trans"><p>在其他百时美施贵宝的新闻中，执行副总裁 David V. Elkins 于 9 月 2 日星期二出售了 56,000 股公司的股票。股票以平均价格 47.33 美元出售，总价值为 2,650,480.00 美元。交易完成后，该执行副总裁直接持有 167,379 股公司股票，估值约为 7,922,048.07 美元。这代表其持股减少了 25.07%。该出售在向证券交易委员会提交的文件中披露，可以通过 SEC 网站访问。内部人士持有公司股票的 0.09%。</p>
</div><h2>Bristol Myers Squibb Stock Down 0.9%</h2>
<div class="lb-trans"><h2>百时美施贵宝股票下跌 0.9%</h2>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
</div><p>NYSE BMY opened at $48.64 on Friday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The stock has a market capitalization of $99.02 billion, a PE ratio of 19.61, a PEG ratio of 2.23 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The business's 50-day moving average is $45.35 and its 200 day moving average is $46.71.</p>
<div class="lb-trans"><p>周五，纽约证券交易所 BMY 的开盘价为 48.64 美元。百时美施贵宝公司的 1 年最低价为 42.52 美元，1 年最高价为 63.33 美元。该股票的市值为 990.2 亿美元，市盈率为 19.61，市盈增长比率为 2.23，贝塔系数为 0.33。公司的债务与股本比率为 2.54，流动比率为 1.21，速动比率为 1.11。该公司的 50 日移动平均线为 45.35 美元，200 日移动平均线为 46.71 美元。</p>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the prior year, the company posted $1.80 EPS. Bristol Myers Squibb's quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近于 10 月 30 日星期四发布了季度财报。这家生物制药公司报告季度每股收益为 1.63 美元，超出分析师一致预期的 1.52 美元，超出幅度为 0.11 美元。百时美施贵宝的股本回报率为 80.04%，净利润率为 10.58%。该公司在本季度的收入为 122.2 亿美元，而分析师预期为 117.5 亿美元。在去年同期，该公司发布的每股收益为 1.80 美元。百时美施贵宝的季度收入较去年同期增长了 2.8%。百时美施贵宝已将其 2025 财年的指导目标设定为每股收益 6.400-6.600 美元。卖方分析师预测百时美施贵宝公司今年的每股收益将达到 6.74 美元。</p>
</div><h2>Bristol Myers Squibb Dividend Announcement</h2>
<div class="lb-trans"><h2>百时美施贵宝分红公告</h2>
</div><ul>
<li>Weak Guidance from Bristol-Myers Could Be Creating an Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>百时美施贵宝的疲软指引可能创造机会</li>
</ul>
</div><p>The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.1%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb's payout ratio is presently 83.78%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，已于 11 月 3 日星期一支付。10 月 3 日星期五的股东获得每股 0.62 美元的分红。这相当于年化分红 2.48 美元，收益率为 5.1%。该分红的除息日为 10 月 3 日星期五。百时美施贵宝的派息比率目前为 83.78%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several brokerages have recently commented on BMY. Sanford C. Bernstein reiterated a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Weiss Ratings reaffirmed a &#34;hold (c-)&#34; rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Morgan Stanley reissued a &#34;hold&#34; rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Daiwa America lowered shares of Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, August 5th. Finally, Daiwa Capital Markets lowered Bristol Myers Squibb from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Four research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. According to MarketBeat.com, Bristol Myers Squibb has an average rating of &#34;Hold&#34; and an average target price of $54.58.</p>
<div class="lb-trans"><p>几家券商最近对 BMY 发表了评论。Sanford C. Bernstein 在 11 月 3 日星期一的研究报告中重申了对百时美施贵宝股票的 “市场表现” 评级。Weiss Ratings 在 10 月 14 日星期二的研究报告中重申了对百时美施贵宝股票的 “持有（c-）” 评级。摩根士丹利在 7 月 31 日星期四的研究报告中重新发布了对百时美施贵宝股票的 “持有” 评级。大和美国在 8 月 5 日星期二将百时美施贵宝的评级从 “强力买入” 下调至 “持有”。最后，大和资本市场在 8 月 5 日星期二将百时美施贵宝的评级从 “跑赢大盘” 下调至 “中性”，并设定了 42.00 美元的目标价。四位研究分析师对该股票给予了买入评级，十五位分析师对该公司给予了持有评级。根据 MarketBeat.com 的数据，百时美施贵宝的平均评级为 “持有”，平均目标价为 54.58 美元。</p>
</div><p><strong>Read Our Latest Analysis on BMY</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 BMY 的最新分析</strong></p>
</div><h2>About Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>关于百时美施贵宝</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供用于血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。公司的产品包括 Eliquis，用于降低非瓣膜性房颤患者中风/全身性栓塞的风险，以及用于治疗深静脉血栓/肺栓塞；Opdivo 用于多种抗癌适应症，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用于多发性骨髓瘤；Orencia 用于活动性类风湿关节炎和银屑病关节炎；Sprycel 用于治疗费城染色体阳性慢性髓性白血病。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>dLocal Falls Despite Blowout Q3 Results—What Investors Are Missing</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>Ondas Holdings Signals a Rebound as Drone Demand Soars</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>Disney’s 2026 Outlook Brightens Under Iger's Magic Touch</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过百时美施贵宝</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>尽管第三季度业绩出色，dLocal 股价仍下跌——投资者错过了什么</li>
<li>市盈率计算：如何评估股票</li>
<li>Ondas Holdings 在无人机需求激增中发出反弹信号</li>
<li>什么样的股票是好的分红股票？</li>
<li>在艾格的魔力下，迪士尼 2026 年的前景变得更加光明</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑百时美施贵宝之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

安联集团 (ADR) 减少了在百时美施贵宝公司 $BMY 的持仓